دورية أكاديمية
أعرض في EDS

Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients.

التفاصيل البيبلوغرافية
العنوان: Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients.
المؤلفون: Leest PV; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Boonstra PA; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Elst AT; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Kempen LCV; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Tibbesma M; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Koopmans J; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Miedema A; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Tamminga M; Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Groen HJM; Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Reyners AKL; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Schuuring E; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
المصدر: Cancers [Cancers (Basel)] 2020 May 13; Vol. 12 (5). Date of Electronic Publication: 2020 May 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Circulating cell-free DNA (ccfDNA) may contain DNA originating from the tumor in plasma of cancer patients (ctDNA) and enables noninvasive cancer diagnosis, treatment predictive testing, and response monitoring. A recent multicenter evaluation of workflows by the CANCER-ID consortium using artificial spiked-in plasma showed significant differences and consequently the importance of carefully selecting ccfDNA extraction methods. Here, the quantity and integrity of extracted ccfDNA from the plasma of cancer patients were assessed. Twenty-one cancer patient-derived cell-free plasma samples were selected to compare the Qiagen CNA, Maxwell RSC ccfDNA plasma, and Zymo manual quick ccfDNA kit. High-volume citrate plasma samples collected by diagnostic leukapheresis from six cancer patients were used to compare the Qiagen CNA (2 mL) and QIAamp MinElute ccfDNA kit (8 mL). This study revealed similar integrity and similar levels of amplified short-sized fragments and tumor-specific mutants comparing the CNA and RSC kits. However, the CNA kit consistently showed the highest yield of ccfDNA and short-sized fragments, while the RSC and ME kits showed higher variant allelic frequencies (VAFs). Our study pinpoints the importance of standardizing preanalytical conditions as well as consensus on defining the input of ccfDNA to accurately detect ctDNA and be able to compare results in a clinical routine practice, within and between clinical studies.
References: J Natl Cancer Inst. 2018 Sep 1;110(9):929-934. (PMID: 29931312)
Nat Rev Cancer. 2011 Jun;11(6):426-37. (PMID: 21562580)
Mol Oncol. 2017 Mar;11(3):295-304. (PMID: 28164427)
Cancer Genet. 2018 Dec;228-229:21-27. (PMID: 30553469)
Sci Transl Med. 2014 Feb 19;6(224):224ra24. (PMID: 24553385)
Oncotarget. 2017 Sep 21;8(49):86253-86263. (PMID: 29156792)
Nat Rev Cancer. 2017 Apr;17(4):223-238. (PMID: 28233803)
Virchows Arch. 2017 Dec;471(6):809-813. (PMID: 28840321)
Cancer Genet. 2018 Dec;228-229:143-150. (PMID: 29567030)
Oncotarget. 2018 Feb 14;9(17):13870-13883. (PMID: 29568401)
Anal Bioanal Chem. 2014 Oct;406(26):6499-512. (PMID: 24853859)
Oncotarget. 2017 Jun 27;8(26):43180-43191. (PMID: 28574818)
Clin Chem. 2020 Jan 1;66(1):149-160. (PMID: 31628139)
Biochim Biophys Acta. 2007 Jan;1775(1):181-232. (PMID: 17137717)
Nature. 2013 May 2;497(7447):108-12. (PMID: 23563269)
Nature. 2012 Jun 28;486(7404):537-40. (PMID: 22722843)
Transl Lung Cancer Res. 2020 Aug;9(4):1093-1100. (PMID: 32953488)
Mol Oncol. 2020 Mar;14(3):487-489. (PMID: 32017376)
PLoS One. 2013 Oct 18;8(10):e77963. (PMID: 24205045)
Front Oncol. 2019 Mar 05;9:129. (PMID: 30891428)
Nat Rev Genet. 2019 Feb;20(2):71-88. (PMID: 30410101)
Sci Transl Med. 2018 Nov 7;10(466):. (PMID: 30404863)
Cancers (Basel). 2020 Apr 07;12(4):. (PMID: 32272669)
NPJ Genom Med. 2018 Nov 23;3:31. (PMID: 30479833)
Clin Biochem. 2013 Oct;46(15):1561-5. (PMID: 23769817)
Cancer Res. 2019 Mar 15;79(6):1204-1213. (PMID: 30573519)
Cancer Res. 2001 Feb 15;61(4):1659-65. (PMID: 11245480)
Crit Rev Clin Lab Sci. 2009;46(1):1-24. (PMID: 19107649)
Clin Cancer Res. 2014 Mar 15;20(6):1698-1705. (PMID: 24429876)
Sports Med. 2012 Jul 1;42(7):565-86. (PMID: 22694348)
Cell. 2016 Jan 14;164(1-2):57-68. (PMID: 26771485)
Virchows Arch. 2019 Jun;474(6):681-689. (PMID: 31028539)
Prenat Diagn. 2010 May;30(5):418-24. (PMID: 20306459)
Clin Chim Acta. 2013 Sep 23;424:222-30. (PMID: 23727028)
Mol Oncol. 2019 Feb;13(2):392-402. (PMID: 30516338)
Cancer Med. 2017 Oct;6(10):2297-2307. (PMID: 28940814)
Cancers (Basel). 2020 Jun 16;12(6):. (PMID: 32560092)
Nat Biotechnol. 2016 May;34(5):547-555. (PMID: 27018799)
Clin Chem. 2015 Jan;61(1):112-23. (PMID: 25388429)
BMC Cancer. 2018 Aug 9;18(1):804. (PMID: 30092778)
Cancer Metastasis Rev. 2016 Sep;35(3):347-76. (PMID: 27392603)
Clin Chim Acta. 2011 Nov 20;412(23-24):2085-8. (PMID: 21861994)
فهرسة مساهمة: Keywords: ccfDNA; ctDNA; extraction; integrity; yield
تواريخ الأحداث: Date Created: 20200517 Latest Revision: 20240328
رمز التحديث: 20240329
مُعرف محوري في PubMed: PMC7281769
DOI: 10.3390/cancers12051222
PMID: 32414097
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers12051222